Shares of Inspire Medical Systems (INSP) surged 11.80% on Tuesday, following the company's impressive third-quarter financial results, raised full-year guidance, and a notable analyst upgrade. The medical device company, known for its innovative sleep apnea treatment, outperformed market expectations and demonstrated strong growth prospects.

Inspire Medical reported a quarterly adjusted earnings per share (EPS) of $0.38, significantly beating the analyst consensus estimate of $(0.19). This represents a remarkable 295.88% surprise to the upside. The company's Q3 revenue reached $224.5 million, surpassing analyst estimates of $221.1 million and marking a 10.49% increase year-over-year. In response to the strong performance, Inspire Medical raised its full-year outlook, now expecting diluted net income per share to be between $0.90 and $1.00, up from previous estimates.

Adding to the positive momentum, Wells Fargo upgraded Inspire Medical to Overweight from Equal Weight, although they adjusted their price target to $90 from $101. This upgrade reflects growing confidence in the company's future prospects. The successful transition to the new Inspire V system appears to be a key driver behind the stock's rally. The system has received positive feedback from clinicians, with reports of 100% successful device implants and reduced surgical times. This transition has not only contributed to revenue growth but also improved gross margins due to lower cost of goods sold.

Despite the strong results and upgrade, it's worth noting that several analysts have adjusted their price targets for Inspire Medical, with some lowering them. JP Morgan cut its target price to $82 from $110, while Jefferies reduced its target to $81 from $85. These adjustments suggest that while the company's performance is impressive, there may be some caution regarding future valuation. Nevertheless, the overall market reaction remains decidedly positive, as evidenced by the significant stock price surge.